A phase I safety and immunogenicity trial of a combination vaccine (neftat and gp120w61d) formulated with AS02A (GlaxoSmithKline Biologicals) given intramuscularly in HIV-1 uninfected adult participants.

Trial Profile

A phase I safety and immunogenicity trial of a combination vaccine (neftat and gp120w61d) formulated with AS02A (GlaxoSmithKline Biologicals) given intramuscularly in HIV-1 uninfected adult participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Nov 2010

At a glance

  • Drugs HIV vaccine (Primary)
  • Indications HIV infections
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top